Residual circulating tumor DNA after adjuvant chemotherapy effectively predicts recurrence of stage II‐III gastric cancer

Abstract

Residual ctDNA after ACT effectively predicts high recurrence risk in stage II/III GC, and the combination of tissue-based and circulating tumor features could achieve better risk prediction.